Celgene pays $280m to settle off-label marketing lawsuit
Whistleblower case relating to cancer prescriptions
US biotech firm Celgene has agreed to pay $280 million (£211 million) to settle a lawsuit over the company promoting its drugs Thalomid and Revlimid for off-label uses.